What SEC filings does Caris Life Sciences, Inc. submit to the SEC?

Caris Life Sciences, Inc. (CAI) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about CAI?

A Form 4 for CAI discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Caris Life Sciences, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for CAI?

The 10-K is Caris Life Sciences, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all CAI SEC filings directly on EDGAR?

You can view all historical Caris Life Sciences, Inc. filings on the SEC EDGAR company page for CAI. Each filing card on this page links directly to the original SEC document.

How often does Caris Life Sciences, Inc. file with the SEC?

Caris Life Sciences, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling CAI shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

CAI SEC Filing News — Caris Life Sciences, Inc.

Latest SEC filings for Caris Life Sciences, Inc. (CAI) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-23.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; …

Sector: Healthcare Industry: Biotechnology Market Cap: $8.7B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for CAI currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

CAI Filing Activity Snapshot 2026-08-05 — 2026-09-23

Insider Transactions (Form 4)

0 buys vs 3 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$14.83M

Spetzler David Baxley (President) · 2026-09-04

597,212 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for Caris Life Sciences, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 8 compensation award and 3 open-market sale. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×8: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×3: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-09-23

CAI insider Denton John Russel (See Remarks) sold 7,500 shares (~$238.6K)

Denton John Russel, listed as See Remarks at Caris Life Sciences, Inc., reported an open-market sale of 7,500 CAI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	7,500	$31.82	$238.6K

Filing: Form 4 (Insider Transaction) Insider: Denton John Russel (See Remarks) Shares: 7,500 Est. Value: $238.6K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-17

CAI insider Brille Brian J (Director, See Remarks) sold 400,000 shares (~$12.13M)

Brille Brian J, listed as Director, See Remarks at Caris Life Sciences, Inc., reported an open-market sale of 400,000 CAI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	400,000	$2.44	$976.0K
`S`	Open-market sale	400,000	$30.33	$12.13M
`M`	Option exercise derivative · Stock Option	400,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Brille Brian J (Director, See Remarks) Shares: 400,000 Est. Value: $12.13M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-04

CAI insider Spetzler David Baxley (President) sold 597,212 shares (~$14.83M)

Spetzler David Baxley, listed as President at Caris Life Sciences, Inc., reported an open-market sale of 597,212 CAI shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	1,000,000	$2.44	$2.44M
`S`	Open-market sale	393,100	$24.76	$9.73M
`S`	Open-market sale	84,900	$25.32	$2.15M
`M`	Option exercise	250,000	$2.44	$610.0K
`S`	Open-market sale	119,212	$24.76	$2.95M
`M`	Option exercise derivative · Stock Option	1,000,000	—	—
`M`	Option exercise derivative · Stock Option	250,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Spetzler David Baxley (President) Shares: 597,212 Est. Value: $14.83M

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

CASTLEMAN PETER M (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: CASTLEMAN PETER M (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

PHILLIPS T DANNY (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: PHILLIPS T DANNY (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

Minor Lloyd (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: Minor Lloyd (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

Gilliam Joseph E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: Gilliam Joseph E (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

Fredrickson David Paul (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: Fredrickson David Paul (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

Vacirca Jeff L (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: Vacirca Jeff L (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

JOHANSEN LAURA I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: JOHANSEN LAURA I (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

CAI insider Form 4 filed for equity award, exercise, or tax withholding

HALBERT JON (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	13,192	—	—

Filing: Form 4 (Insider Transaction) Insider: HALBERT JON (Director) Shares: 13,192

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 6 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Caris Life Sciences, Inc. has 6 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-22

CAI Form 144 filed for proposed insider sale by JOHN RUSSEL DENTON (7,500 shares) ~$238.6K

JOHN RUSSEL DENTON filed a Form 144 with the SEC indicating intent to sell CAI (Caris Life Sciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOHN RUSSEL DENTON Shares: 7,500 Est. Value: $238.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Large Proposed Insider Sale 2026-09-17

CAI Form 144 filed for proposed insider sale by BRIAN J BRILLE (400,000 shares) ~$12.13M

BRIAN J BRILLE filed a Form 144 with the SEC indicating intent to sell CAI (Caris Life Sciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: BRIAN J BRILLE Shares: 400,000 Est. Value: $12.13M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-04

CAI Form 144 filed for proposed insider sale by DAVID SPETZLER (119,212 shares) ~$2.95M

DAVID SPETZLER filed a Form 144 with the SEC indicating intent to sell CAI (Caris Life Sciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: DAVID SPETZLER Shares: 119,212 Est. Value: $2.95M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-03

CAI Form 144 filed for proposed insider sale

An insider at Caris Life Sciences, Inc. filed a Form 144 notifying the SEC of an intent to sell shares. Form 144 is a proposed sale notice rather than confirmation that a sale already happened.

Filing: Form 144 (Proposed Sale Notice)

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-24

CAI Form 144 filed for proposed insider sale by GEORGE H POSTE REVOCABLE TRUST (100,000 shares) ~$2.61M

GEORGE H POSTE REVOCABLE TRUST filed a Form 144 with the SEC indicating intent to sell CAI (Caris Life Sciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: GEORGE H POSTE REVOCABLE TRUST Shares: 100,000 Est. Value: $2.61M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-07

CAI Form 144 filed for proposed insider sale by GEORGE H POSTE (30,000 shares) ~$642.6K

GEORGE H POSTE filed a Form 144 with the SEC indicating intent to sell CAI (Caris Life Sciences, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: GEORGE H POSTE Shares: 30,000 Est. Value: $642.6K

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Caris Life Sciences, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-14

CAI filed 8-K — material company event

Caris Life Sciences, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-05

CAI filed 8-K — material company event

Caris Life Sciences, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Caris Life Sciences, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

CAI filed Quarterly Report (10-Q)

Caris Life Sciences, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Caris Life Sciences, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CAI. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CAI SEC Filings

More Tools for CAI

CAI Full Stock Analysis CAI Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CAI analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CAI stock analysis page.

CAI Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer